Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Glucagon

Xeris Glucagon to be Branded "Gvoke"; Xeris Issues 5M Additional Shares

Here is a brief preview of this blast: Xeris announced a proposed public offering of 5M additional shares; and, in the S-1 document, disclosed the commercial name of its stable glucagon as "Gvoke" believed to be pronounced (gee'-voke), which appears to be a play on the word "evoke."   Below, FENIX provides key highlights from the S-1 filing, thoughts on the impending Xeris glucagon launch in H2 '19 (June 10, 2019 PDUFA date), and insight on potential read-through to Xeris from FDA's upcoming decisions on Sanofi/Lexicon's sotagliflozin in T1DM (March 22, 2019 PDUFA date) and Lilly's nasal glucagon (PDUFA believed to be in April 2019).

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.